Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs

被引：0
作者：
Chen, Y. [1 ]
Lin, H. M. [2 ]
Wan, Y. [2 ]
Yin, Y. [2 ]
Wu, Y. [2 ]
Hernandez, L. [3 ]
Danes, C. [3 ]
Churchill, E. N. [3 ]
Dimou, A. [4 ]
机构：
[1] Canc & Hematol Ctr, Grand Rapids, MI USA
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] Takeda Pharmaceut USA Inc, Lexington, MA USA
[4] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Brigatinib; Real-world data; ALK plus NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.02
引用
收藏
页码：S641 / S641
页数：1
相关论文
共 50 条
  • [1] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
    Ahn, M. -J.
    Delmonte, A.
    Ghosh, S.
    Hochmair, M.
    Yang, T. -Y.
    Yang, J. C. -H.
    Han, J. -Y.
    Hansen, K. Holmskov
    Wu, Y.
    Wan, Y.
    Lin, H. M.
    Kretz, J.
    Hupf, B.
    Kurec, A. M.
    Churchill, E. N.
    Fram, R. J.
    Cabasag, C. J.
    Goriya, V.
    Zhao, Y.
    Gemmen, E.
    Campelo, M. R. Garcia
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
  • [2] Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK plus NSCLC in the US
    Wan, Y.
    Ren, K.
    Lin, H. M.
    Wu, Y.
    Humphries, M. J.
    Zhang, P.
    Jahanzeb, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S478 - S479
  • [3] Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
    Kim, Kyuhwan
    Kim, Kyu Yean
    Kang, Hye Seon
    Shin, Ah Young
    Kim, Sung Kyoung
    Park, Chan Kwon
    Lee, Sang Haak
    Kim, Seung Joon
    Lim, Jeong Uk
    Yeo, Chang Dong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [4] Lorlatinib for ALK plus NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
    Ng, R.
    Zuraik, C.
    On, P. V.
    Khoudigian, S.
    Sharma, A.
    Peloquin, F.
    Aita, F. Fanton
    Rupp, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S450 - S450
  • [5] Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
    Goto, Y.
    Emir, B.
    Kaneyasu, K.
    Kikkawa, H.
    Wiltshire, R.
    Shukuya, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [6] Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients
    Davies, Jessica
    Martinec, Michael
    Coudert, Mathieu
    Delmar, Paul
    Crane, Gracy
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (03) : 535 - 542
  • [7] LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
    Alexander, Marliese
    Wei, Joe
    Parakh, Sagun
    John, Thomas
    Kao, Steven
    Nagrial, Adnan
    Bowyer, Samantha
    Warburton, Lydia
    Moore, Melissa
    Hughes, Brett G. M.
    Clay, Timothy D.
    Pavlakis, Nick
    Solomon, Benjamin J.
    Itchins, Malinda
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (04):
  • [8] Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
    Bauman, Jessica R.
    Liu, Geoffrey
    Preeshagul, Isabel
    Liu, Stephen V.
    Melosky, Barbara
    Abrahami, Devin
    Li, Benjamin
    Thomaidou, Despina
    Duncan, Kirsten
    Krulewicz, Stan
    Rupp, Martin
    Lin, Jessica J.
    LUNG CANCER, 2024, 195
  • [9] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [10] ALK Testing in Chinese Advanced NSCLC Patients: A National-Wide Multicenter Prospective Real-World Data Study (The RATICAL Study)
    Ying, J.
    Li, L.
    Li, W.
    Li, Y.
    Xia, Q.
    Teng, X.
    Liu, Y.
    Chen, G.
    Qiu, X.
    Wu, W.
    Ji, Y.
    Wang, Z.
    Yan, X.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S497 - S497
12345